The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19.

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2024-05-01 Epub Date: 2024-01-08 DOI:10.1080/14787210.2024.2303017
Jheng-Yan Wu, Mei-Yuan Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Shu-Ching Tseng, Chih-Ying Lu, Chih-Cheng Lai
{"title":"The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19.","authors":"Jheng-Yan Wu, Mei-Yuan Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Shu-Ching Tseng, Chih-Ying Lu, Chih-Cheng Lai","doi":"10.1080/14787210.2024.2303017","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the outcomes of underweight patients with COVID-19 and the effectiveness of antiviral agents in this population.</p><p><strong>Methods: </strong>A retrospective cohort study using theTriNetX research network was conducted. Propensity score matching (PSM) was employed to balance the first cohort involving COVID-19 patients with underweight and normal-weight. In the second cohort, underweight patients receiving antiviral agents and untreated individuals were matched using PSM. The primary outcome was a composite of all-cause hospitalization and death during the 7-30-day follow-up period.</p><p><strong>Results: </strong>After PSM, the first cohort including each group of 13,502 patients with balanced baseline characteristics were identified for comparing the outcome of patients with underweight and normal weight. The underweight group had a higher risk of the composite primary outcome than those with normal weight (hazard ratio [HR], 1.251; 95% confidence interval [CI], 1.132-1.382). The second cohort included each 884 underweight patients with and without receiving antivirals.Compared with untreated patients, those receiving antiviral treatment had a lower risk of composite primary outcomes (HR, 0.426; 95% CI, 0.278-0.653).</p><p><strong>Conclusion: </strong>Underweight status may be associated with a higher risk of all-cause hospitalization and death in patients with COVID-19.Among underweight patients, antiviral agents demonstrated clinically beneficial effects.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2303017","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study investigated the outcomes of underweight patients with COVID-19 and the effectiveness of antiviral agents in this population.

Methods: A retrospective cohort study using theTriNetX research network was conducted. Propensity score matching (PSM) was employed to balance the first cohort involving COVID-19 patients with underweight and normal-weight. In the second cohort, underweight patients receiving antiviral agents and untreated individuals were matched using PSM. The primary outcome was a composite of all-cause hospitalization and death during the 7-30-day follow-up period.

Results: After PSM, the first cohort including each group of 13,502 patients with balanced baseline characteristics were identified for comparing the outcome of patients with underweight and normal weight. The underweight group had a higher risk of the composite primary outcome than those with normal weight (hazard ratio [HR], 1.251; 95% confidence interval [CI], 1.132-1.382). The second cohort included each 884 underweight patients with and without receiving antivirals.Compared with untreated patients, those receiving antiviral treatment had a lower risk of composite primary outcomes (HR, 0.426; 95% CI, 0.278-0.653).

Conclusion: Underweight status may be associated with a higher risk of all-cause hospitalization and death in patients with COVID-19.Among underweight patients, antiviral agents demonstrated clinically beneficial effects.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体重不足的 COVID-19 患者的临床结果和抗病毒药物的有效性。
研究目的本研究调查了 COVID-19 低体重患者的预后以及抗病毒药物在这一人群中的有效性:方法:利用TriNetX研究网络开展了一项回顾性队列研究。采用倾向得分匹配法(PSM)平衡了第一组涉及 COVID-19 患者的体重不足和体重正常的人群。在第二个队列中,使用 PSM 对接受抗病毒药物治疗的体重不足患者和未接受治疗的患者进行了匹配。主要结果是在 7-30 天的随访期间所有原因住院和死亡的复合结果:结果:经过 PSM,确定了包括每组 13,502 名患者在内的第一个队列,这些患者的基线特征均衡,可用于比较体重过轻和体重正常患者的预后。体重不足组比体重正常组的综合主要结局风险更高(危险比 [HR],1.251;95% 置信区间 [CI],1.132-1.382)。与未接受治疗的患者相比,接受抗病毒治疗的患者发生综合主要结局的风险较低(HR,0.426;95% CI,0.278-0.653):体重不足可能与 COVID-19 患者全因住院和死亡的风险较高有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
期刊最新文献
The opportunities and challenges of epigenetic approaches to manage herpes simplex infections. Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis ‎coinfection‎. Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. Is self-medication with antibiotics among the public a global concern: a mixed-methods systematic review. Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1